The Journal of Urology
Volume 180, Issue 3 , Pages 1146-1153 , September 2008

Is Vascular Endothelial Growth Factor Modulation a Predictor of the Therapeutic Efficacy of Gefitinib for Bladder Cancer?

  • Wassim Kassouf

      Affiliations

    • Division of Urology, McGill University Health Center, Montreal, Quebec, Canada
    • ,
  • Gordon A. Brown

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Peter C. Black

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Mark B. Fisher

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Teruo Inamoto

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Tony Luongo

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • David Gallagher

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Menashe Bar-Eli

      Affiliations

    • Department of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • David J. McConkey

      Affiliations

    • Department of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Liana Adam

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Colin P.N. Dinney

      Affiliations

    • University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Corresponding Author InformationCorrespondence: Department of Urology, Unit 1373, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (telephone: 713-792-3250; FAX: 713-794-4824).
    • Financial interest and/or other relationship with AstraZeneca, GlaxoSmithKline, National Cancer Institute, Canji/Schering-Plough and Abbott/Vysis.

Received 22 December 2007

References 

  1. Crew JP. Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer. Eur Urol. 1999;35:2
  2. Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004;171:570
  3. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183
  4. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs. 2000;60(suppl.):25
  5. Mendelsohn J, Dinney CP. The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy. J Urol. 2001;165:1152
  6. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 2001;7:1459
  7. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve B, Hicklin D, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999;5:257
  8. Paez JG, Janne PA, Lee JC, Tracey S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497
  9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129
  10. Kassouf W, Dinney CP, Brown G, McConkey D, Diehl A, Bar-Eli M, et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells. Cancer Res. 2005;65:10524
  11. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4
  12. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001;49:568
  13. Li CY, Shan S, Huang Q, Braun R, Lanzen J, Hu K, et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst. 2000;92:143
  14. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669
  15. Ellis LM, Staley CA, Liu W, Fleming RY, Parikh NU, Bucana CD, et al. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem. 1998;273:1052
  16. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res. 2000;60:5879
  17. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 1998;58:2288
  18. Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao WJ, et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 2006;12:4671

 Study received institutional animal care and use committee approval.

 Supported by National Cancer Institute Cancer Center Core Grant CA16672, GU Bladder SPORE CA91846 and a T32 training grant.

PII: S0022-5347(08)01221-4

doi: 10.1016/j.juro.2008.05.001

The Journal of Urology
Volume 180, Issue 3 , Pages 1146-1153 , September 2008

Article Tools

* Image Usage & Resolution